CD8A and neoplasm: Bispecific antibodies targeting CD47 and PD‐L1 (CD47 × PD‐L1 BisAb) demonstrate efficacy against a range of solid cancers, but the effect of combined innate and adaptive immune activation on protective tumor‐resident CD8+ T cells has yet to be fully elucidated.